Found 10327 clinical trials
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of mutations in the
- 250 views
- 25 May, 2021
- 14 locations
Study in Parkinson Disease of Exercise
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax …
- 0 views
- 04 Jun, 2021
- 8 locations
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis
This is a Phase 1, multicenter, dose-escalation, open-label study to assess safety, tolerability, preliminary activity, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate-2 or high-risk myelofibrosis.
- 0 views
- 09 Jun, 2021
- 4 locations
An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol® (doxercalciferol capsules) in Pediatric Patients with Chronic Kidney Disease Stages 3 and 4 with Secondary Hyperparathyroidism Not Yet on Dialysis
This is a randomized, open label, parallel, active comparator study in patients aged 5– 18 years with Chronic Kidney Disease (CKD) Stages 3 and 4 and secondary hyperparathyroidism (SHPT) not
- 45 views
- 11 Jun, 2020
- 1 location
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction
participants with Large Hemispheric Infarction (LHI). The secondary objectives are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093
- 12 views
- 12 Aug, 2020
- 1 location
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- 0 views
- 17 May, 2021
- 1 location
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- 0 views
- 17 May, 2021
- 1 location
AnaLysIs of Both Sex and Device Specific FactoRs on Outcomes in PAtients with Non-Ischemic Cardiomyopathy - Bio Libra
Secondary Objectives All-cause mortality, VT or VF alone, risk of cardiac death, and sudden cardiac death for the total cohort, as well as by sex and by the implanted
- 48 views
- 24 Nov, 2020
- 1 location
QUILT -2.023: A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC
This is a phase 2, open-label, randomized study to compare the safety and efficacy of combination therapy with ALT-803 and pembrolizumab (experimental arm) versus pembrolizumab alone (control arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.
- 0 views
- 31 Mar, 2021
- 1 location
Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease
This study will determine if a dexamethasone mouth rinse can reduce the risk of developing oral chronic graft-versus-host disease (cGVHD) in patients who have undergone a bone marrow (stem cell) transplant procedure. cGVHD is a common complication of stem cell transplantation, resulting from the donor cells attacking the transplant recipient's …
- 38 views
- 22 Dec, 2020
- 1 location